Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisine Repeat-Dose PK/PD in Healthy Smokers
NCT03303911Phase 2Terminated
- Sponsor
- Achieve Life Sciences
- Start
- Oct 2017
- Primary completion
- Oct 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised trial of cytisinicline in nicotine dependence (2 arms), sponsored by Achieve Life Sciences. Primary endpoints: Maximum Observed Plasma Concentration at Day 25, Time of Occurrence of Cmax at Day 25 and 13 more. Started Oct 2017; status: terminated.
02
Drugs
cytisinicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03303911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303911.